A Phase 2 interventional study of 60 milligrams of ENERGI-F705 Tablets and Placebo tablets in Parkinson's Disease (PD), sponsored by Energenesis Biomedical Co., Ltd.. Not yet recruiting at 2 sites in Taiwan. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Energenesis Biomedical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 121 studies in Parkinson Disease with a site in Taiwan — 33 open to participants now, 37 under way, 1 of them phase 3. Parkinson Disease · Taiwan.
Among the 121 studies in Parkinson Disease with a site in Taiwan, this one is the 18th largest by planned enrollment of the 99 interventional ones that give a count, is one of 7 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 35 of the 36 other live ones, and was the 118th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →33 of the 121 studies in Parkinson Disease with a site in Taiwan are open now. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
Serina Therapeutics · Sites in Taiwan, United States, Australia
Ages 40–80
Hoffmann-La Roche · Sites in Taiwan, United States, Australia and 14 more countries
Ages 50–85
National Taiwan University Hospital · Sites in Taiwan
Ages 18+ · Healthy volunteers
National Taiwan University Hospital · Sites in Taiwan
Ages 18–80
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
121 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 9 · Phase 4 2
First in 2005; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 105 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 55 across the 99 interventional studies, 92 across the 22 observational. Of the 58 that completed or were terminated, 9 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 121 have an industry lead sponsor. The 10 most frequent:
Energenesis Biomedical Co., Ltd. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Energenesis Biomedical Co., Ltd. has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
11 of the studies in Parkinson Disease with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06548256Kaohsiung Medical University Chung-Ho Memorial HospitalThe Clinical Application of Clostridium Butyricum Miyairisan for Motor and Non-motor Symptoms in Parkinson's Disease | 2026-12-31 |
| NCT07422675Serina TherapeuticsSAD Study in Patients With Parkinson's Disease and Motor Fluctuations | 2027-01-31 |
| NCT07172295National Taiwan University HospitalModulate Tremor Severity With Low-intensity Focused Ultrasound Stimulation Targeting the Deep Nucleus of Patients With Refractory Hand Tremor. | 2027-06-30 |
| NCT07028515National Taiwan University HospitalSelf-controlled Practice on Motor Learning and Motivation in Parkinson's Disease | 2027-07-31 |
| NCT07294469Taipei Medical University HospitalMenthol for Improving Movement and Sleep in Parkinson's Disease Patients | 2027-07-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 121 studies in Parkinson Disease with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if this study drug, ENERGI-F705 Tablets, is safe and works to treat participants who have Parkinson's disease and are currently on standard-of-care antiparkinsonian medications. The main question it aims to answer is:
Does ENERGI-F705 Tablets work to treat Parkinson's disease when used with standard-of-care treatment?
Investigators will compare the three treatment groups, high-dose ENERGI-F705 Tablets (120 milligrams twice daily), low-dose ENERGI-F705 Tablets (60 milligrams twice daily), and placebo tablets (a look-alike substance that contains no drug), to see if ENERGI-F705 Tablets work to treat Parkinson's disease.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A subject is eligible for the study if all of the following apply:
Has received a stable standard-of-care regimen, as determined by the investigator, during the 12 weeks prior to Visit 2 (Day 1) and is currently on the following antiparkinsonian medications with an average levodopa equivalent daily dose (LEDD) of ≥ 300 mg during the same period, including:
Has adequate indices as follows at Visit 1 (Screening Visit):
Exclusion Criteria:
Any subject meeting any of the exclusion criteria will be excluded from study participation:
Has any of the following neurosurgical intervention for Parkinson's disease within 2 years prior to or at Visit 2 (Day 1):
With ongoing or a documented history of within 2 years prior to or at Visit 2 (Day 1) of acute diseases or severe medical conditions, including:
Administered dopamine-blocking agents within 12 weeks prior to or at Visit 2 (Day 1), including:
Has participated in another clinical trial involving an investigational product, medical device, or surgical procedure within 4 weeks prior to Visit 1 (Screening Visit)
* Note: Subjects enrolled in non-interventional clinical trials will be eligible.
Female subject with who is lactating or has positive serum or urine pregnancy test at Visit 2 (Day 1)
* Note: Female subjects with any of following conditions are considered not with childbearing potential
Female subjects with childbearing potential or male subjects with partners of childbearing potential who refuse to use highly effective from signing until the end of study (EOS) or early termination (ET) visit
* Note: At least two forms of birth control must be adopted and one of which must be a barrier method. Acceptable forms include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
60 milligrams of ENERGI-F705 Tablets
Drug: 60 milligrams of ENERGI-F705 Tablets
120 milligrams of ENERGI-F705 Tablets
Drug: 120 milligrams of ENERGI-F705 Tablets
Placebo tablets
Drug: Placebo tablets
Tablets will be taken orally twice a day
Tablets will be taken orally twice a day.
Tablets will be taken orally twice a day.
Number of participants experiencing adverse events (AE) and serious adverse events (SAE)
All AEs and SAEs will be assessed following National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.
Time frame: From Day 1 to Week 76
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score
MDS-UPDRS Part III is a scale used by the investigator to evaluate motor functions of Parkinson's disease. The total score ranges from 0 to 132. The higher score indicates more difficulties with movements.
Time frame: Baseline to Week 72
MDS-UPDRS Part IV score
MDS-UPDRS Part IV is a scale used by the investigator to evaluate the motor complications in Parkinson's disease. The total score ranges from 0 to 24 with the higher score indicating greater impact on the daily life due to motor complications.
Time frame: Baseline to Week 72
Sum of MDS-UPDRS Part I score, MDS-UPDRS Part II score and MDS-UPDRS Part III score
* MDS-UPDRS Part I is a scale, consisting of Part IA (conducted by healthcare professionals) and Part IB (participant's self-assessment), to assess how non-motor symptoms impact daily living. The total score ranges from 0 to 52. The higher score indicates more non-motor symptoms or greater impact on the activities of daily living due to non-motor symptoms. * MDS-UPDRS Part II is a participant's self-assessment to observe how motor symptoms affect your daily living. The total score ranges from 0 to 52. The higher score indicates more motor symptoms or greater impact on the activities of daily living. * MDS-UPDRS Part III is a scale used by the investigator to evaluate motor functions of Parkinson's disease. The total score ranges from 0 to 132. The higher score indicates more difficulties with movements.
Time frame: Baseline to Week 72
Proportion of participants with 3-point or more increase in MDS-UPDRS Part III score
MDS-UPDRS Part III is a scale used by the investigator to evaluate motor functions of Parkinson's disease. The total score ranges from 0 to 132. The higher score indicates more difficulties with movements.
Time frame: Baseline to Week 72
Time to onset of motor complication
The motor complication events are collected from the MDS-UPDRS Part IV, a scale to evaluate the motor complication in Parkinson's disease. The total score ranges from 0 to 24 with the higher score indicating greater impact on the daily life due to motor complications.
Time frame: From Day 1 to Week 72
Non-motor symptoms scale (NMSS) total score
NMSS is a scale to assess non-motor symptoms in Parkinson's disease. It contains 9 subdomains and the total score ranges from 0 to 360. The higher score indicates greater burden of non-motor symptoms.
Time frame: Baseline to Week 72
Parkinson's Disease Questionnaire-39 (PDQ-39) total score
PDQ-39 score is to assess the health-related quality of life with Parkinson's disease. The total score is transformed into a percentage score between 0 to 100 with higher percentage indicating worsen health-related quality of life due to Parkinson's disease.
Time frame: Baseline to Week 72
Modified Hoehn and Yahr stage
Modified Hoehn and Yahr stage is a scale to evaluate severity of Parkinson's disease in 8 stages. The staging ranges from Stage 0 (No sings of disease) to Stage 5 (Wheelchair bound or bedridden unless aided).
Time frame: Baseline to Week 72
Levodopa equivalent daily dose (LEDD) of antiparkinsonian medications
The doses of antiparkinsonian medications will be converted into levodopa equivalent daily dose (LEDD, mg).
Time frame: Baseline to Week 72
Time to the first LEDD adjustment
It refers to the changes in LEDD amount (defined as a ≥10% change in LEDD).
Time frame: From Day 1 to Week 72
Number of participants with abnormalities in vital signs
Vital signs measurement consist of systolic and diastolic blood pressure, respiratory rate, pulse rate, and body temperature.
Time frame: Baseline to Week 76
Number of participants with abnormalities in laboratory examination results
Laboratory examinations consist of the followings: * Hematology: hemoglobin, hematocrit, red blood cell (RBC), platelet, white blood cell (WBC) with differential counts, prothrombin time, international normalized ratio (INR), and activated partial thromboplastin time (APTT) * Biochemistry: total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), uric acid, blood urea nitrogen (BUN), serum albumin, creatinine, and estimated glomerular filtration rate (eGFR) * Urinalysis: color, appearance, specific gravity, pH, protein, glucose, occult blood, ketones, leukocyte esterase, nitrite, bilirubin, urobilinogen, and microscopic examination of urine sediment
Time frame: Baseline to Week 76
Number of participants with toxicity grade change for the laboratory examination results
Toxicity grading will be assessed according to the NCI-CTCAE version 6.0.
Time frame: Baseline to Week 76
Number of participants with abnormalities in physical examination
Physical examinations include general appearance, skin, eyes, ears, nose, throat, head and neck (including thyroid), heart, chest and lungs, abdomen, extremities, lymph nodes, musculoskeletal, neurological system, and other body systems if applicable for describing the status of the subject's health.
Time frame: Baseline to Week 76
Number of participants with transition of electrocardiogram results
The results of ventricular rate, PR interval, QRS interval, QT interval, RR interval, and QTcB will be recorded.
Time frame: Baseline to Week 72
Adenosine triphosphate (ATP) levels in whole blood samples
The ATP level will be measured using a qualified analytical method at a contracted central laboratory.
Time frame: Baseline to Week 76
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jan 2030, 37 months later.
Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's planned 37 months is above that.
Counting every sponsor, half of 203 studies reached it within 28 months; a quarter within 16 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Energenesis Biomedical Co., Ltd. →